Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market Overview
- Overview of Cancer
- Prostate Cancer
- Biology of Prostate Cancer
- Symptoms
- Screening
- Diagnosis
- Localized Prostate Cancer
- Metastatic Prostate Cancer
- Watchful Waiting or Active Surveillance
- Treatment
- Conclusions
Chapter 4 Market Dynamics
- Overview
- Market Drivers
- Increasing Prevalence of Prostate Cancer
- Active Surveillance and Screening
- Personalized Care
- Approvals for Metastatic Castration-Resistant Prostate Cancer
- Collaborations and Licensing Agreements
- Market Challenges
- Loss of Exclusivity and Genericization
- Shortage of Care Providers and Other Resources
- Market Opportunities
Chapter 5 Screening and Diagnosis Market by Test Type
- Market Overview
- Biomarker Tests
- PSA Tests
- Limitations of PSA Tests
- Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
- Digital Rectal Exam
- Limitations of DREs
- Prostate Biopsy
- Grade (Gleason Score) of Prostate Cancer
- Prostatic Intraepithelial Neoplasia
- Atypical Small Acinar Proliferation
- Proliferative Inflammatory Atrophy
- Intraductal Carcinoma of the Prostate
- Limitations of Prostate Biopsies
- Imaging Technologies for Prostate Cancer
- Market for Prostate Cancer Screening/Diagnosis, by Test Type
- Biomarker Tests
- DREs
- Prostate Biopsies
Chapter 6 Pharmaceuticals Market by Drug Type
- Market Overview
- Hormone Therapy
- Androgen Deprivation Therapy
- Antiandrogen Therapies
- Hormone Therapy Uses in Prostate Cancer Treatment
- Targeted Therapy
- PARP Inhibitors
- Radioligand Therapies
- Small Molecule Targeted Agents
- Monoclonal Antibodies
- Chemotherapy
- Immunotherapy
- Market Revenue, by Drug Type
- Hormone Therapy
- Targeted Therapy
- Immunotherapy
- Chemotherapy
Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type
- Market Overview
- Active Surveillance
- Radical Prostatectomy
- Robotic Prostatectomy
- Open Radical Prostatectomy
- Laparoscopic Prostatectomy
- Radical Prostatectomy Market Revenue
- Radiation Therapy
- External Beam Radiation Therapy
- Brachytherapy
- Combined Radiation Therapy
- Radiation Therapy Device Market Revenue
Chapter 8 Market Breakdown by Region
- Market Overview
- Market Revenue, by Region
- North America
- Market Revenue, by Product Type
- Europe
- Market Revenue, by Product Type
- Asia-Pacific
- Market Revenue, by Product Type
- Rest of the World (RoW)
- Market Revenue, by Product Type
Chapter 9 Emerging Technologies and Developments
- Overview
- Liquid Biopsy
- Multiparametric MRI
- Homologous Recombination Repair Gene Mutation
- Advanced Radiotherapy Techniques
- AI and Machine Learning
Chapter 10 Pipeline Analysis
Chapter 11 Competitive Intelligence
- Overview
- Screening and Diagnosis Market
- Market for Radiation Therapy Devices
- Pharmaceuticals Market
Chapter 12 Company Profiles
- ABBOTT
- ACCURAY INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA PLC
- BAYER AG
- DANAHER CORP.
- DENDREON PHARMACEUTICALS LLC
- ELEKTA
- F. HOFFMANN-LA ROCHE LTD.
- JOHNSON & JOHNSON SERVICES INC.
- PFIZER INC.
- SANOFI
- SIEMENS HEALTHINEERS AG
List of Tables
Summary Table: Global Market for Prostate Cancer Care, by Type, Through 2028
Table 1: Four Stages of Prostate Cancer
Table 2: Prostate Cancer: Local and Metastatic Symptoms
Table 3: Current Prostate Cancer Treatment Options
Table 4: Prostate Cancer: Major Points
Table 5: Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040
Table 6: Key Biomarkers for Prostate Cancer
Table 7: First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023
Table 8: ACS, NCCN and USPSTF Guidelines on PSA Screening Tests
Table 9: Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 10: NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening
Table 11: Imaging Technologies for Prostate Cancer
Table 12: Prostate Cancer Screening and Diagnostic Methods
Table 13: Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 14: Hormone Therapy Drugs Approved for Prostate Cancer Treatment
Table 15: PARP Inhibitors Approved for Prostate Cancer Treatment
Table 16: Radioligand Drugs Approved for Prostate Cancer Treatment
Table 17: Chemotherapy Drugs Approved for Prostate Cancer Treatment
Table 18: Immunotherapy Approved for Prostate Cancer Treatment
Table 19: Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028
Table 20: Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 21: Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 22: Treatment Options for Prostate Cancer
Table 23: Advantages and Disadvantages of Radical Prostatectomy
Table 24: Global Market for Radical Prostatectomy, Through 2028
Table 25: Comparison of Low- and High-Dose Radiation Therapy
Table 26: Comparison of EBRT and Brachytherapy
Table 27: Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, Through 2028
Table 28: Advances in EBRT
Table 29: Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028
Table 30: North American Market for Prostate Cancer Care, by Product Type, Through 2028
Table 31: North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 32: Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020
Table 33: European Market for Prostate Cancer Care, by Product Type, Through 2028
Table 34: European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 35: Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040
Table 36: Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028
Table 37: Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 38: RoW Market for Prostate Cancer Care, by Product Type, Through 2028
Table 39: Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 40: PARP Inhibitors in Phase 3 Clinical Trials
Table 41: Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023
Table 42: Prostate Cancer Drugs Pipeline (Phase III Industry Trials)
Table 43: Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022
Table 44: Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022
Table 45: Abbott: Company Snapshot
Table 46: Abbott: Financial Performance, FY 2021 and 2022
Table 47: Abbott: Prostate Cancer Product Portfolio
Table 48: Accuracy Inc.: Company Snapshot
Table 49: Accuracy Inc.: Financial Performance, FY 2022 and 2023
Table 50: Accuray Inc.: Radiotherapy Product Portfolio
Table 51: Accuray Inc.: Recent Developments, 2022-2023
Table 52: Astellas Pharma Inc.: Company Snapshot
Table 53: Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022
Table 54: Astellas Pharma Inc.: Prostate Cancer Drug Portfolio
Table 55: Astellas Pharma Inc.: Recent Developments, 2021-2023
Table 56: AstraZeneca Plc: Company Snapshot
Table 57: AstraZeneca Plc: Financial Performance, FY 2021 and 2022
Table 58: AstraZeneca Plc: Prostate Cancer Drug Portfolio
Table 59: AstraZeneca Plc: Recent Developments, 2022-2023
Table 60: Bayer AG: Company Snapshot
Table 61: Bayer AG: Financial Performance, FY 2021 and 2022
Table 62: Bayer AG: Prostate Cancer Drugs Portfolio
Table 63: Bayer AG: Recent Developments, 2021-2023
Table 64: Danaher Corp.: Company Snapshot
Table 65: Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 66: Danaher Corp.: Prostate Health Product Portfolio
Table 67: Dendreon Pharmaceuticals LLC: Company Snapshot
Table 68: Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
Table 69: Elekta: Company Snapshot
Table 70: Elekta: Financial Performance, FY 2022 and 2023
Table 71: Elekta: Radiotherapy Product Portfolio
Table 72: Elekta: Recent Developments, 2021-2023
Table 73: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 74: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
Table 75: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 76: F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
Table 77: Johnson & Johnson Services, Inc.: Company Snapshot
Table 78: Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
Table 79: Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
Table 80: Johnson & Johnson Services, Inc.: Recent Developments, 2023
Table 81: Pfizer Inc.: Company Snapshot
Table 82: Pfizer Inc.: Financial Performance, FY 2021 and 2022
Table 83: Pfizer Inc.: Prostate Cancer Drugs Portfolio
Table 84: Pfizer Inc.: Recent Developments, 2022-2023
Table 85: Sanofi: Company Snapshot
Table 86: Sanofi: Financial Performance, FY 2021 and 2022
Table 87: Sanofi: Prostate Cancer Drug Portfolio
Table 88: Sanofi: Recent Developments, 2022
Table 89: Siemens Healthineers: Company Snapshot
Table 90: Siemens Healthineers: Financial Performance, FY 2022 and 2023
Table 91: Siemens Healthineers: Prostate Cancer Product Portfolio
Table 92: Siemens Healthineers: Recent Developments, 2022-2023
Table 93: Abbreviations Used in this Report
List of Figures
Summary Figure A: Global Market for Prostate Cancer Care, by Type, 2020-2028
Summary Figure B: Global Market Shares of Prostate Cancer Care, by Type, 2022
Figure 1: Cancer Care Spectrum
Figure 2: Prostate Cancer Risk Group
Figure 3: Prostate Cancer Advancements
Figure 4: Prostate Cancer Care Market Dynamics
Figure 5: Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040
Figure 6: Share of Prostate Cancer Cases, by Stage
Figure 7: Prostate Cancer Incidence in the U.S.
Figure 8: Cancer Radiotherapy Systems Treatment, by Region, 2021
Figure 9: Prostate Cancer 5-Year Relative Survival Rates
Figure 10: Trends in Oncology
Figure 11: Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028
Figure 12: Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022
Figure 13: Benefits of Immunotherapy
Figure 14: Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028
Figure 15: Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022
Figure 16: Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 17: Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 18: Global Market for Radical Prostatectomy, 2020-2028
Figure 19: Types of Radiation
Figure 20: Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028
Figure 21: Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022
Figure 22: Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region
Figure 23: Global Market Shares of Prostate Cancer Screening, Diagnosis and Treatment, by Region, 2022
Figure 24: Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040
Figure 25: North American Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 26: European Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 27: Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040
Figure 28: Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 29: RoW Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 30: Emerging Technologies in Prostate Cancer Care
Figure 31: Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023
Figure 32: Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023
Figure 33: Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022
Figure 34: Abbott: Revenue Share, by Business Unit, FY 2022
Figure 35: Abbott: Revenue Share, by Region, FY 2022
Figure 36: Accuray Inc.: Revenue Share, by Product Type, FY 2023
Figure 37: Accuray Inc.: Revenue Share, by Region, FY 2023
Figure 38: Astellas Pharma Inc.: Revenue Share, by Product, 2022
Figure 39: Astellas Pharma Inc.: Revenue Share, by Region, 2022
Figure 40: AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
Figure 41: AstraZeneca Plc: Revenue Share, by Region, 2022
Figure 42: Bayer AG: Revenue Share, by Business Segment, 2022
Figure 43: Bayer AG: Revenue Share, by Region, 2022
Figure 44: Danaher Corp.: Market Share, by Business Segment, 2022
Figure 45: Danaher Corp.: Revenue Share, by Region, 2022
Figure 46: Elekta: Revenue Share, by Product Type, 2023
Figure 47: Elekta: Revenue Share, by Region, 2023
Figure 48: F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022
Figure 49: F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
Figure 50: Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022
Figure 51: Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022
Figure 52: Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 53: Pfizer Inc.: Revenue Share, by Region, 2022
Figure 54: Sanofi: Revenue Share, by Global Business Unit, 2022
Figure 55: Sanofi: Revenue Share, by Region, 2022
Figure 56: Siemens Healthineers: Revenue Share, by Segment, 2023
Figure 57: Siemens Healthineers: Revenue Share, by Region, 2023
